Drug Trial Radar · NCT05722262
Study to Demonstrate the Bioequivalence of Single Oral Administration of K-001 Relative to Single Oral Coadministration of Separate Tablets of K-877-ER and CSG452
Last checked: Nov 19, 2026Latest source record: Jun 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Feb 24, 2023
Primary completion
Apr 1, 2023
Study completion Apr 5, 2023
Sponsor
- Lead sponsor
- Kowa Research Institute, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Supportive care
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to demonstrate the bioequivalence of single oral administration of K-001 relative to single oral co-administration of separate tablets of K-877-ER and CSG452 in healthy adult volunteers, and to characterize the food effect on the Pharmacokinetics(PK) of K-001.
Conditions
- Healthy
Interventions
K-001Drug
K-877-ER and CSG452 combination tablet
K-877-ERDrug
K-877-ER tablet
CSG452Drug
CSG452 tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax of K-877 and CSG452Time frame: 1 hour before dosing and at multiple time points (up to 48 hours) post dose
- AUC0-t of K-877 and CSG452Time frame: 1 hour before dosing and at multiple time points (up to 48 hours) post dose
- AUC0-inf of K-877-and CSG452Time frame: 1 hour before dosing and at multiple time points (up to 48 hours) post dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PPD - Austin Research Unit
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.